Skip to main content
JOHNSON & JOHNSON logo

JOHNSON & JOHNSON — Investor Relations & Filings

Ticker · JNJ ISIN · US4781601046 LEI · 549300G0CFPGEF6X2043 US Manufacturing
Open in API
Filings indexed 3,142 across all filing types
Latest filing 2011-05-27 Regulatory Filings
Country US United States of America
Listing US JNJ

About JOHNSON & JOHNSON

https://www.jnj.com/

Johnson & Johnson is a healthcare company that operates through two primary segments: Innovative Medicine and MedTech. The Innovative Medicine division is focused on the research, development, and delivery of new treatments for complex diseases in areas such as oncology, immunology, neuroscience, and cardiopulmonary conditions. The MedTech segment develops and provides a broad portfolio of medical technologies and solutions. It innovates in fields including surgery, orthopaedics, vision, and interventional solutions, aiming to create smarter, less invasive, and more personalized healthcare treatments. The company's mission is to address significant health challenges through science-based innovation at the intersection of biology and technology.

Recent filings

Filing Released Lang Actions
Regulatory Filings 2011
Regulatory Filings Classification · 95% confidence The document is a letter from Johnson & Johnson's Vice President Corporate Controller to the SEC responding to comments on the company's previously filed Form 10-K for the fiscal year ended January 2, 2011. It addresses specific SEC staff comments regarding disclosures in the 10-K, including research and development activities, income taxes, and accounting policies. The letter does not contain the full annual report or financial statements itself but is a regulatory correspondence related to the 10-K filing. The document length is about 12,565 characters, which is substantial but the content is clearly a comment response letter rather than the report itself. According to the rules, such correspondence responding to SEC comments on a 10-K is classified as a Regulatory Filing (RNS) because it is a regulatory communication and not the actual annual report or audit report. Therefore, the appropriate classification is Regulatory Filings (RNS).
2011-05-27 English
425 Filing
Merger & Acquisition Classification · 95% confidence The document is a customer letter from Johnson & Johnson regarding the proposed acquisition of Synthes, Inc. It references the filing of a registration statement on Form S-4 with the SEC, which will include a proxy statement/prospectus related to the acquisition. The letter urges shareholders to read the proxy materials once filed. The document is a communication about the upcoming merger transaction and the related filings, not the filings themselves. It does not contain financial statements or detailed financial analysis but rather serves as an informational letter about the merger process and regulatory filings to come. The presence of forward-looking statements and disclaimers further supports that this is a communication piece rather than a formal report. Given the content and length (about 10,600 characters), it is not a brief announcement but a detailed communication related to merger activity. The document fits best under the category of Merger & Acquisition (MA) filings, which include merger communications such as Form 425 filings. Therefore, the classification is MA with high confidence.
2011-05-23 English
FORM 8-K
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K current report filed by Johnson & Johnson dated May 17, 2011. The content focuses on the announcement of an underwriting agreement for the issuance and sale of various notes (debt securities) with specific principal amounts and maturity dates. It includes details about the underwriting parties, terms of the notes, and legal opinions attached as exhibits. There are no financial statements or comprehensive financial performance data presented, nor is this a full annual or quarterly report. The primary subject is the company's financing activity related to debt issuance. According to the filing definitions, updates on company fundraising or financing activities fall under Capital/Financing Update (CAP). The document length is under 5,000 characters but contains substantive information about the financing transaction itself, not merely an announcement of a report. Therefore, the correct classification is CAP with high confidence.
2011-05-20 English
424B5
Capital/Financing Update Classification · 95% confidence The document is a detailed prospectus supplement and prospectus for a securities offering by Johnson & Johnson, specifically for various series of notes (floating rate notes and fixed rate notes) with detailed terms, interest rates, maturity dates, underwriting information, and use of proceeds. It includes registration statement information filed pursuant to Rule 424(b)(5) under the Securities Act of 1933, which is a common filing for securities offerings. The content focuses on the issuance of debt securities and related financing details, not on financial results, management commentary, or regulatory certifications. This matches the definition of a Capital/Financing Update (CAP), which covers updates on company fundraising and financing activities. The document is lengthy (15,000 characters) and contains substantive details about the offering, not just an announcement or a brief notice, so it is not a Report Publication Announcement (RPA) or Regulatory Filing (RNS). Therefore, the correct classification is CAP with high confidence.
2011-05-19 English
FWP
Capital/Financing Update Classification · 100% confidence The document is a Pricing Term Sheet for a debt security issuance by Johnson & Johnson, describing terms of 0.700% Senior Unsecured Notes due 2013. It includes details such as coupon rate, maturity date, size, underwriting discount, and settlement date. The document is filed pursuant to Rule 433, which relates to free writing prospectuses used in securities offerings. This is a capital markets document providing information about a financing transaction rather than a financial report or regulatory filing. It is not an annual or interim report, earnings release, or management discussion. It is not a proxy, voting result, or governance document. The content clearly fits the category of Capital/Financing Update (CAP), which covers updates on company fundraising and financing activities.
2011-05-19 English
FWP
Capital/Financing Update Classification · 100% confidence The document is a Pricing Term Sheet for Floating Rate Notes due 2014 issued by Johnson & Johnson. It details the terms of a debt security offering, including coupon, maturity, interest payment dates, calculation agent, and underwriting details. The document is filed pursuant to Rule 433, which relates to free writing prospectuses used in securities offerings. It is not a financial report, earnings release, or management discussion. It is a capital markets document providing information about a debt issuance and its terms. Therefore, it fits best under the category of Capital/Financing Update (CAP), which covers updates on company fundraising and financing activities.
2011-05-19 English

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.